Debt-free Balance SheetA zero-debt balance sheet reduces fixed financing costs and lowers solvency risk, giving NextCell flexibility to fund clinical programs via equity, partnerships, or grants. For a development-stage biotech this structural strength lengthens strategic options and reduces downside from interest burdens.

Recurring Stem Cell Banking RevenueContracted, recurring revenues from Cellaviva's stem cell banking create a steadier cash base than pure R&D firms, partially funding operations and de-risking near-term financing needs. This service line diversifies income away from milestone-driven biopharma cycles and supports longer runway for ProTrans development.

Consistent Revenue GrowthSustained top-line growth indicates commercial traction in the company's service offerings and a growing customer base. Over the medium term, continued revenue expansion can drive operating leverage, improve cash generation potential, and reduce per-unit R&D burden as fixed costs are spread across higher volumes.

Bears Say

Deep UnprofitabilityPersistent negative gross profit and a massively negative net margin indicate core operations and product economics are not yet sustainable. Without material gross-margin improvement, the company cannot self-fund growth and must rely on external capital or partnerships, increasing execution risk over months.

Ongoing Cash BurnSustained negative operating and free cash flow (~-43M FY2025) erodes runway and forces serial financing, which can dilute shareholders or constrain strategic choices. Even if burn improved recently, the absolute outflow necessitates durable funding plans to advance clinical milestones over the next 2–6 months.

Shrinking Equity / Dilution RiskA marked decline in equity reflects cumulative losses and likely past equity raises, signaling dilution risk and a weakened capital base. This structural erosion reduces financial headroom, can compress investor returns, and makes future fundraising more dilutive or costly, impacting long-term shareholder value.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.29 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €15.09M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 99 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.002.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.